Showing 6111-6120 of 7756 results for "".
- Galderma Debuts Sensitive Skincare Facultyhttps://practicaldermatology.com/news/galderma-debuts-sensitive-skincare-faculty/2461372/Reinforcing its commitment to advancing dermatology for every skin story, Galderma has formed a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives. The Faculty will focus on three key pillars of research, innovation, and engagem
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- BeautyHealth Introduces Hydrafacial x JLo Beauty Boosterhttps://practicaldermatology.com/news/beautyhealth-introduces-the-hydrafacial-x-jlo-beauty-booster/2461369/The BeautyHealth Company is rolling out the Hydrafacial x JLo Beauty Booster . “I'm so excited to partner with Hydrafacial to create the new JLo Beauty Booster,” says founder of JLo Beauty Jennifer Lopez in a news release. “Hydrafacial is one of my favorite treatme
- Galderma, NBCF Partner to Launch Campaign Elevating Skin Stories of Breast Cancer Survivorshttps://practicaldermatology.com/news/galderma-nbcf-partner-to-launch-campaign-elevating-skin-stories-of-breast-cancer-survivors/2461366/Galderma is continuing its partnership with National Breast Cancer Foundation Inc. (NBCF) with a new campaign that elevates the skin stories of breast cancer survivors. Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who received Re
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- L'Oréal Breaks Ground on New Research and Innovation Center in NJhttps://practicaldermatology.com/news/loreal-breaks-ground-on-new-research-and-innovation-center-in-nj/2461361/L'Oréal USA is opening a new, state-of-the-art Research & Innovation (R&I) Center in Clark, New Jersey, replacing its existing facilities that it has occupied in the area for more than six decades. The $140 million development project represents the most significant investment
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the
- Ortho Dermatologics Names 2022 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2022-aspire-higher-scholarship-recipients/2461356/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently named the recipients of their 2022 Aspire Higher Scholarship program. The program, which has provided a total of $918,000 in scholarships since launching in 2013, will award nine students who have been treate
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). &ldquo